ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Two View Mammography Said Less Costly Than One In Screening

April 25, 1986

DCT Program Cutbacks Planned as Research Stressed In 4 Cancers

February 26, 1993

Human Embryo Panel Defines Acceptable Research For Funding

September 30, 1994

Cancer Registry Says Paper By Jon Sudbo Was Based On Fabricated Data.

January 27, 2006

ASCO Ends Early Distribution Of Abstracts To Halt “ASCO Effect” On Stock Market

January 24, 2003

NALSO Members Urged To Police Selves, Adopt Ethics Code

August 4, 1978